Share this link via:
Press Release
New developments in Antibody Drug Conjugates are changing how we approach Precision Oncology. The combination of monoclonal antibodies and chemotherapeutic agents, with their unique ability to direct a potent agent directly to cancer cells, is changing the way we treat cancer patients. The use of new chemical linker technologies will allow us to selectively deliver cytotoxic potency of chemotherapeutic agents to cancer cells while reducing exposure to normal cells and, therefore, the risk of side effects related to chemotherapy treatment.
The ADC market demonstrated exceptional performance in 2023, achieving a valuation of USD 5,475.84 million. Based on current growth trajectories, robust clinical pipeline developments, and increasing regulatory approvals, the market is projected to reach USD 8,419 million by 2025 representing a remarkable compound annual growth rate (CAGR) of 22.0% during the 2026-2035 forecast period.
The incredible success of this growth is due to the increased number of different types of cancer treatments that are being validated as clinically safe by ADC technology. Currently there are over 140 different ADCs that are either in preclinical trials or have completed Phase I through III and have received regulatory approval from multiple regulatory agencies. There are many factors contributing to this tremendous growth in ADC market; including increasing global cancer incidence, with more than 1.8 million new cases diagnosed every year just in the United States; continued improvement of antibody technology and linker chemistry; strategic support and partnerships between major pharmaceutical companies; and additional uses for ADCs outside of conventional uses for ADCs.
Antibodies in Drug Conjugates are sophisticated biopharmaceutical constructs including three main components working together. A monoclonal antibody binds very specifically to tumor-associated antigens and works to get the chemotherapy drug to the right cancer cells while not hitting healthy cells. A cytotoxic payload associated with Antibody Drug Conjugates has a stronger effect on tumor cells than traditional chemotherapy drugs due to its potency (100 - 1,000 times) over that of traditional drugs. The chemical structure linking the Mab to the cytotoxin provides a stable connection when circulating in vivo and allows for release of the cytotoxin once the Mab enters the target cell.
The unprecedented growth in the ADC market has been catalyzed by a multitude of factors that are interconnected and influence both the clinical need and technological ability. The largest contributing factor to this growth is the ever-increasing global cancer burden, as indicated by the World Health Organization, which cites that cancer is the second leading cause of death worldwide and accounts for one out of every six deaths. In the United States in 2019, there were 1.8 million new cancer cases 870,970 in men and 891,480 in women indicating that there are many patients who require advanced forms of therapeutic treatment.
Factors contributing to the rising incidence of cancer may consist of demographic change through age, behavior change through lifestyle, and exposure from the environment. A report provided by the Skin Care Foundation demonstrates that from 1994 to 2014, there were 77% more cases of non-melanoma skin cancer than previously; of all cases of non-melanoma skin cancers, more than 90% were related to exposure to ultraviolet radiation. These epidemiological trends are indicative of continuous and urgent need for developing new and better ways of treating cancer, thus improving the chance of survival for patients while ensuring their quality of life.
Advancements in technology serve as a key driver of continued growth within the ADC (antibody-drug conjugate) market, as pharmaceutical companies invest heavily in their ADC R&D programs. The AACR (American Association for Cancer Research), for example, has supported over 800 scientists studying many different aspects of tumor biology through the distribution of more than US$5 million through 634 grant awards to support their research. Modern ADC development incorporates advanced methods for antibody design that allow for precise location of conjugation, as well as optimized linker chemistry that allows for controlled release of drug payloads from antibodies, together with enhanced pharmacokinetic properties of ADCs that allow them to be used at higher concentrations in both solid and blood cancers.
The strategic partnerships and collaborative efforts formed between companies have led to a significant increase in the speed of commercialization of ADC products. This is well evidenced by Merck's December 2022 exclusive licensing agreement with Kelun Biotech (for seven investigational ADCs), as well as Merck's collaboration with Daiichi Sankyo in 2023 to develop the three DXd platform ADCs, both of which demonstrate the pharmaceutical industry's recognition of the unique opportunity presented by these innovative products. Through the combination of both the complementary technological capabilities of ADCs and the global commercialization infrastructure of the participating companies, these partnerships will be key in helping to reduce the time required to bring new products to market and to expand the potential patient populations eligible to receive them.
While there are projections for strong growth in the ADC sector, multiple factors could slow the rate of growth for many ADCs. The primary limitation on the use of ADCs is the toxicities that can occur when treating patients with ADC therapy to normal (healthy) tissue; patients can experience serious chronic complications from ADC therapy, including cardiovascular dysfunction, renal impairments, peripheral neuropathy, and increased risk of developing a second malignancy, as reported by the Mayo Clinic. These safety issues will require careful patient selection and monitoring protocols to ensure appropriate use and therefore may limit access to ADC treatment for certain patient populations.
Another obstacle to growth in the ADC sector is the complexity of manufacturing ADCs, as both biological manufacturing and the manufacturing of high potency cytotoxic require highly sophisticated facilities. As a result, developing and manufacturing ADCs increases the amount of required capital investment, lengthens the development time to bring a product to market, and increases the overall cost of goods sold (COGS), which may affect the ability for manufacturers to implement pricing strategies and market access in regions where the cost sensitivity is high.
In markets where the incidence of cancer is on the rise, many geographic locations fall under this criterion due to their low level of service; therefore, many geographic locations within the ADC subsector remain relatively untapped for future business growth. There are several large populations of untreated breast, lung, gastric, and liver cancers in Asia Pacific countries, particularly China, India, and Southeast Asian Countries; thus, utilizing ADC therapy would offer better clinical outcomes than what can be achieved today without ADC therapies.
By developing next-gen ADC technology that uses new linker chemistries, alternate Cytotoxic Payloads other than MMAE and DM4 agents, as well as innovative Targeting Strategies, significantly more patients should be treated with ADC therapies. Examples of emerging strategies are bispecific ADCs, smaller antibody formats yielding greater tumor penetration and conditional activation strategies.
Monoclonal antibodies are the leading product in the ADC market, with an estimated 66% market share of total ADC sales in 2023 and are anticipated to grow at an outstanding compound annual growth rate (CAGR) of 28.5% over the forecast period. The reason for this segment's leadership is due to monoclonal antibodies’ remarkable targeting ability of tumor-associated antigens, their superior pharmacokinetic properties that permit an extended half-life in circulation and a high concentration in the tumor compared to other classes of therapeutic agents, as well as a well-established manufacturing base created from years of experience developing therapeutic monoclonal antibodies.
Most currently marketed ADCs use chimeric or fully humanized antibodies to reduce risk of immunogenicity while retaining the ability to bind to their intended target antigen. As the ADC market expands, the use of genetically engineered human (recombinant) antibodies will continue to provide significant improvements in clinical therapeutic performance. Importantly, genetic engineering of the human antibody has improved clinical performance in lowering the incidence of neutralizing antibody responses, increasing half-lives of serum, and allowing for multiple doses of the same ADC without a loss of efficacy. Ultimately, the selection of target antigens for ADCs can significantly impact the ability for an ADC to provide a therapeutic benefit to patients, with well-established target antigens including HER2 in breast cancers, CD22 in B-cell malignancies, CD30 in lymphomas, and Trop-2 in carcinomas and other epithelial tumors.
Linker technology is one of a variety of sophisticated components found in antibody drug conjugates (ADCs) that are utilized to determine both circulation stability and intracellular characteristics of drug payload release. The cleavable linkers have a large market demand from customers, especially peptide-based valine-citrulline constructs, which cleave specifically by cathepsin proteases, which are found in high abundance within the cell lysosome of tumor cells. In addition to providing stability to the drug conjugates in circulation, cleavable linkers provide for the continued stability of the payload once the drug has been taken up by the targeted cells.
Adcetris is the most popular product in this market segment, generating USD 2,742.3 million in revenue and accounting for nearly 50% of the overall market. Adcetris is an example of a chimeric Antibody-drug Conjugate made from an anti-CD30 monoclonal antibody bound to the cytotoxic monomethyl auristatin E (MMAE) using a protease cleavable valine-citrulline linked conjugate. Adcetris has been approved for several indications including Hodgkin lymphoma, systematic anaplastic, large cell lymphoma, and peripheral T-cell lymphomas.
Kadcyla (ado-trastuzumab emtansine) is another commercially important antibody-drug conjugate. Kadcyla uses trastuzumab as the antibody component, DM1 maytansine as the cytotoxic payload, and a non-cleavable thioether linker. Kadcyla was initially approved for use in HER2-positive metastatic breast cancer but has evolved into an adjuvant treatment option allowing for improved patient outcomes in malignancies that possess already available target-specific treatments.
Currently, breast cancer is one of the largest segments of the market for Antibody Drug Conjugates (ADCs). This is due to a combination of the high prevalence of breast cancer, the various types of breast cancer and how breast cancer can be treated with different types of ADCs (i.e., the various HER2+ medications). Other targets that were previously only associated with ADCs for HER2+ breast cancer have also expanded the current use of ADCs in triple-negative or hormone receptor-positive breast cancer. Patients with triple-negative or hormone receptor-positive breast cancer will have no other targeted therapies available to them.
Hematologic malignancies are also a large application segment for ADCs, with several products that have been approved for the treatment of these cancers. The targets for these ADCs include CD30, CD22, CD33, and BCMA which all selectively target lymphomas, leukemias, and multiple myeloma without damaging normal tissue.The last category labelled 'Other' includes ADC use in lung and colorectal and urothelial cancers and is projected to be the fastest growing ADC segment as additional cancers begin to use ADCs.
The North American region is establishing itself as the dominant player in terms of the overall percentage of the global market. Major growth drivers for North America include the United States having one of the most advanced health care systems, many pharmaceutical companies, and favorable regulations. According to the National Cancer Institute, as of 2018 there were approximately 1,735,350 new cases of cancer diagnosed, and 609,640 deaths attributed to cancer. This represents a very high disease burden, which will drive demand for therapeutic intervention.
The Asia-Pacific region has emerged as the fastest-growing segment of the global market, primarily due to the large number of patients who currently have cancer, increasing incidences of cancer diagnoses, and the continued expansion of healthcare systems in this region. Within the Asia-Pacific region, Japan has several biotechnology companies, such as Daiichi Sankyo, that have developed and marketed new and innovative DXd technology platforms. Conversely, China represents the best long-term opportunity for commercialization based on the size of its population and the expansion of its oncology healthcare system.
While Europe has an established market that boasts developed, well-organized healthcare systems and extensive regulatory processes through the EMA, there are significant differences in terms of access to ADCS between key European Markets such as Germany, France and the UK, due to differing rates of ADC adoption among these countries based on their own national reimbursement policies and outcomes from health technology assessments.
The global ADC market is showing moderate amounts of consolidation with existing pharmaceutical companies and niche biotechnology companies competing in all phases of development, approval and commercialization. The current market leaders are those who have built proven ADC technology platforms, have large-scale commercialization platforms for oncology and who have positioned themselves to maximize the revenue potential of high-value indications for cancer.
Gilead Sciences has expanded its presence in the ADC (antibody-drug conjugate) sector through the acquisition of Immunometric to obtain Trodelvy for treating Triple-Negative Breast Cancer (TNBC) and to lay the groundwork for the development of additional ADCs moving forward. With this investment strategy, Gilead believes the excitement and disruptive capabilities of ADC technology will be able to change the current cancer therapeutic landscape and significantly increase the number of products in their oncology product offering.
Pfizer has also established a strong position within the ADC market with its acquisition of Seagen, which gave it access to Adcetris (the first FDA-approved ADC) and allowed it to build a full suite of ADC development competencies. The company's extensive oncology product portfolio and large commercial organization provide Pfizer with the resources necessary to increase the adoption of ADCs and grow the overall ADC market.
Antikor Biopharma is a company that supports the development of formulating (and/or) administering innovator products that are smaller in size than currently available products in the biotechnology industry. Recently, Antikor secured a $3.1-million investment agreement through Essex Bio-Investments that provides an opportunity for the development of innovative technologies that could enable better delivery of therapeutic agents to tumours than traditional conjugate antibodies.
Companies Covered: Roche/Genentech, Takeda Pharmaceutical, Daiichi Sankyo, Pfizer, Gilead Sciences, AbbVie, Astellas Pharma, Seagen, Immunogen, Antikor Biopharma, Celldex Therapeutics, and emerging ADC innovators
"Intellectual Market Insights' ADC market analysis helped us identify the optimal entry strategy for our oncology pipeline, resulting in a successful USD 50M Series B funding round."
- VP Strategy, Leading Biotech Company
In-Depth Company Profiling (15+ Leading ADC Market Players)
Market Segmentation & Growth Analysis
Comprehensive Regional Coverage
Strategic Framework Analysis
End-User Analysis & Market Dynamics
Market Valuation & Financial Intelligence
Regional Market Leadership & Growth Opportunities
Competitive Intelligence & Strategic Positioning
Technology & Innovation Assessment
Market Segmentation Leadership
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
25 Apr 2026
Intellectual Market Insights Research © 2026. All rights reserved.
